中国现在领导全球临床试验,在数量和创新方面超过了美国和欧洲。 China now leads global clinical trials, surpassing the U.S. and Europe in volume and innovation.

中国的临床试验能力现在相当于美国,到2024年,中国在美国进行的试验占80%,超过欧洲10%。 China’s clinical trial capacity now equals that of the United States, with China conducting 80% of trials done in the U.S. and surpassing Europe by 10% as of 2024. 吸引国际制药公司和投资者的新药管道不断增多,刺激了这一增长。 The growth is fueled by a rising pipeline of novel drugs attracting international pharmaceutical companies and investors. 多国公司越来越多地在中国进行调查员发起的试验——特别是在细胞和基因疗法方面——通过更快地获得病人的数据和在推进创新治疗方面的战略优势来进行。 Multinational firms are increasingly pursuing investigator-initiated trials—especially in cell and gene therapies—in China, drawn by faster access to patient data and a strategic advantage in advancing innovative treatments.